Latest Tax Incentives News

Proteomics International Laboratories reported a 26% increase in losses for FY2025, driven by higher operational costs as it advances its Promarker® diagnostic pipeline. Despite an 8% rise in revenue from ordinary activities, total income slipped 2%, underscoring ongoing commercialisation challenges.

Harvest Technology Group reported a reduced net loss of $7.06 million for FY2025 amid restructuring and new funding, while focusing on its remote communications technology segment and launching Project NEON.

COG Financial Services Limited reported a 23% increase in net profit after tax to $18.8 million for FY2025, driven by growth in novated leasing and asset management segments. The company declared a fully franked final dividend of 3.0 cents per share, reflecting a strategic shift towards broking capabilities.

Audeara Limited reported a 19% revenue increase to $3.79 million for FY25, driven by strong Australian wholesale growth and expanding international partnerships. Despite a net loss of $1.79 million, the company’s AUA Technology division and new licensing deals position it for future profitability.

Iondrive Ltd reported a 94.7% surge in revenue to $1.71 million for FY2025, driven by R&D tax incentives and other income, yet still recorded a net loss of $4.62 million amid high expenses. The company also expanded its footprint in Europe by acquiring a German entity.

Starpharma reports a significant 183% jump in FY25 revenue to $4.9 million, alongside a 31% reduction in losses and a solid cash position of $15.4 million. The biotech firm’s progress underscores growing momentum in its dendrimer technology pipeline.

Calix Limited reported a 17% rise in product and services revenue for FY25, driven by its Magnesia and Leilac businesses, alongside a 23% reduction in operating expenses. The company extended its cash runway to 18 months, supported by a $21 million equity raise, while progressing key decarbonisation projects.

Imugene Limited reported a significant 54% reduction in net loss for FY25, driven by cost efficiencies and promising clinical progress in its immuno-oncology pipeline. The company’s lead asset, azer-cel, achieved a 79% response rate in Phase 1b trials and secured FDA Fast Track designation.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

InhaleRx Limited reported a widening half-year loss as it accelerates clinical trials for inhaled drug-device therapies, supported by a substantial $38.5 million funding facility.

Noxopharm has successfully completed the third dosing phase of its HERACLES trial for SOF-SKN™, confirming safety and moving forward to the highest dose cohort in this pioneering autoimmune drug study.